心臟植入器材市场－2025-2030年预测

预计心臟植入设备市场将从 2025 年的 428.45 亿美元成长到 2030 年的 611.01 亿美元，复合年增长率为 7.36%。

心臟植入设备市场分析

心臟植入医疗器材市场是医疗设备产业的重要组成部分，并因心血管疾病盛行率上升和全球人口老化而持续成长。这些器械，例如心臟节律器、置入式除颤器（ICD）和冠状动脉支架，满足了心臟疾病治疗的关键需求。儘管技术进步和支持性医疗政策推动了市场成长，但高成本仍然是一大挑战。

本研究检验了心臟植入医疗器材市场目前的需求、供应和销售趋势，以及近期影响该市场发展的重要因素。研究全面分析了关键驱动因素、阻碍因素和机会，并详细说明了区域产业趋势、政策和法规，帮助相关人员深入了解法规结构和市场动态。

我们的竞争情报是基于广泛的二手研究，包括产业协会调查、分析师报告、投资者报告、新闻稿和学术期刊，旨在识别主要企业及其收入贡献。市场规模采用自下而上和自上而下的方法计算，并透过全球心臟植入设备价值链相关人员的第一手资讯进行验证。我们全面的市场分析整合了各种资讯来源和专有资料集，并运用资料三角验证技术，提供准确的市场区隔和预测。我们透过分析叙述、图表和图形呈现检验，以帮助读者有效率地理解。预计2024年全球市场规模约348亿美元，2030年将达542亿美元，复合年增长率为7.7%。我们将起搏器、ICD和冠状动脉支架的主要製造商列为关键参与者。

主要亮点

• 心血管疾病的流行：病例数不断增加（截至 2024 年，全球有 6 亿人受到影响），推动了对心臟植入的需求。
• 人口老化：预计到 2050 年，全球人口将达到 15 亿，老龄化人口将推动对心臟设备的需求。
• 技术进步：设备设计的创新正在提高效率并推动市场成长。
• 成本障碍：设备成本高昂，平均售价为 20,000 至 50,000 美元，限制了其在对成本敏感的市场的普及。

成长要素

心血管疾病盛行率的不断上升（预计到2024年病例数将增加5%）正显着推动对冠状动脉支架和植入式心臟復律去颤器（ICD）等医疗器材的需求。人口老化，尤其是在北美和欧洲，导致心臟衰竭和心律不整病例增加，增加了对植入治疗的需求。诸如2024年推出的无导线心律调节器等技术创新，正在推动病患疗效的改善和器械普及。政府支持措施，例如印度于2024年实施的10亿美元“医疗保健普及计划”，正在提高亚太地区的医疗可近性。

抑制因素

心臟植入医疗器材的高成本，加上相关的植入费用，限制了其在新兴市场的普及。严格的监管核准要求，例如美国食品药物管理局（FDA）和欧盟医疗设备法规（MDR）（将于2024年进一步收紧），延长了研发週期。发展中地区有限的健保报销政策也阻碍了市场渗透。

細項分析

依产品类型划分：受心臟疾病高发生率的影响，冠状动脉支架将在2024年占据30%的市场份额，稳居榜首。植入式心臟帮浦则因心臟衰竭病例的增加而快速成长。

依应用领域划分：心律不整治疗占比最大，其次是心臟衰竭治疗和冠状动脉疾病治疗。

按最终用户划分：医院占比最大，但由于对微创手术的需求不断增长，门诊诊所的数量也在增加。

区域分析

到2024年，北美将占据40%的市场份额，这主要得益于美国较高的可支配收入和先进的医疗保健基础设施。亚太地区正以9.2%的复合年增长率成长，这主要受中国和印度心血管疾病发病率上升以及医疗保健投资增加的推动。欧洲将凭藉其健全的医疗保健体系和研发投入保持成长势头。

本报告为业内人士提供关于市场趋势、监管环境和竞争动态的关键洞察。报告重点介绍了先进的医疗器材技术和新兴市场机会，同时也探讨了成本和监管方面的挑战。严谨的调查方法，结合一手和二手数据，确保了预测的可靠性，并帮助相关人员理解复杂的市场格局，从而优先考虑在这一重要的医疗设备领域的投资。

本报告的主要优势：

• 深入分析：取得以客户群、政府政策和社会经济因素、消费者偏好、垂直产业和其他细分市场为重点的深入市场洞察，涵盖主要地区和新兴地区。
• 竞争格局：了解主要企业采取的策略倡议，并了解透过正确的策略打入市场的潜力。
• 市场驱动因素与未来趋势：探索动态因素和关键市场趋势，以及它们将如何塑造未来的市场发展。
• 可执行的建议：利用洞察力为策略决策提供讯息，从而在动态环境中开拓新的业务管道和收入来源。
• 受众范围广：对新兴企业、研究机构、顾问公司、中小企业和大型企业都有益处且经济高效。

它是用来做什么的？

产业与市场洞察、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法律规范及其影响、新产品开发、竞争影响

分析范围

• 历史资料（2022-2024 年）和预测资料（2025-2030 年）
• 成长机会、挑战、供应链前景、法规结构、客户行为和趋势分析
• 竞争对手定位、策略和市场占有率分析
• 按业务板块和地区（国家）分類的收入成长和预测分析
• 公司概况（策略、产品、财务资讯、关键趋势等）

目录

第一章执行摘要

第二章市场概述

• 市场概览
• 市场定义
• 分析范围
• 市场区隔

第三章 商业情境

• 市场驱动因素
• 市场限制
• 市场机会
• 波特五力分析
• 产业价值链分析
• 政策和法规
• 策略建议

第四章 技术展望

第五章：依产品类型分類的心臟植入设备市场

• 介绍
• 起搏器
• 心臟再同步治疗（CRT）装置
• 置入式除颤器（ICD）
• 经导管心臟瓣膜（TAVR/TAVI）及外科人工瓣膜
• 心室辅助装置（VAD/LVAD）
• 心臟监测植入
• 左心耳封堵器（LAA封堵器）
• 冠状动脉支架
• 人工心臟瓣膜
• 可植入式心臟监测器（ICM）
• 植入式心臟泵
• 线索、生成器和交付系统
• 其他的

6. 按分销类型分類的心臟植入设备市场

• 介绍
• 三级医院
• 社区医院
• 门诊手术中心
• 心臟诊所

7. 各地区心臟植入器材市场

• 介绍
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 南美洲
  • 巴西
  • 阿根廷
  • 其他的
• 欧洲
  • 英国
  • 德国
  • 法国
  • 义大利
  • 西班牙
  • 其他的
• 中东和非洲
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他的
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 韩国
  • 台湾
  • 泰国
  • 印尼
  • 其他的

第八章 竞争格局与分析

• 主要企业和策略分析
• 市占率分析
• 企业合併、协议、商业合作
• 竞争对手仪錶板

第九章：公司简介

• Medtronic plc
• Abbott Laboratories
• Boston Scientific Corporation
• Edwards Lifesciences Corporation
• Biotronik SE & Co. KG
• LivaNova PLC
• Lepu Medical Technology Co., Ltd.
• Asahi Kasei Corporation（Zoll Medical）
• Abiomed, Inc.
• SynCardia Systems, LLC
• MicroPort Scientific Corporation：

第十章 分析方法

The Cardiac Implant Devices Market is anticipated to rise from USD 42.845 billion in 2025 to USD 61.101 billion by 2030, at a CAGR of 7.36%.

Cardiac Implant Devices Market Analysis

The cardiac implant devices market is a vital segment of the medical device industry, driven by the rising prevalence of cardiovascular diseases and an aging global population. These devices, including pacemakers, implantable cardioverter defibrillators (ICDs), and coronary stents, address critical needs in managing heart conditions. Technological advancements and supportive healthcare policies fuel growth, though high costs pose challenges.

This research examines current trends in demand, supply, and sales, alongside recent developments shaping the cardiac implant devices market. It provides a comprehensive analysis of key drivers, restraints, and opportunities, detailing industry trends, policies, and regulations across geographical regions to equip stakeholders with insights into the regulatory framework and market dynamics.

Competitive intelligence identifies major industry players and their revenue contributions, derived from extensive secondary research, including industry association studies, analyst reports, investor presentations, press releases, and journals. Market size for the overall sector and key segments was determined using bottom-up and top-down methodologies, validated with primary inputs from stakeholders in the global cardiac implant devices value chain. Comprehensive market engineering integrated data from diverse sources and proprietary datasets, employing data triangulation for accurate market breakdown and forecasting. Insights are presented through analytical narratives, charts, and graphics for efficient comprehension. The global market was valued at approximately USD 34.8 billion in 2024 and is projected to reach USD 54.2 billion by 2030, growing at a CAGR of 7.7%. Key players profiled include leading manufacturers of pacemakers, ICDs, and coronary stents.

Key Highlights

• Cardiovascular Disease Prevalence: Rising cases, affecting 600 million globally in 2024, drive demand for cardiac implants.
• Aging Population: A geriatric population of 1.5 billion by 2050 fuels heart disease-related device needs.
• Technological Advancements: Innovations in device design enhance efficacy, boosting market growth.
• Cost Barriers: High device costs, averaging USD 20,000-50,000, limit adoption in cost-sensitive markets.

Growth Drivers

The increasing prevalence of cardiovascular diseases, with a 5% rise in cases in 2024, significantly boosts demand for devices like coronary stents and ICDs. An aging population, particularly in North America and Europe, drives heart failure and arrhythmia cases, necessitating implants. Technological advancements, such as leadless pacemakers introduced in 2024, improve patient outcomes and adoption. Supportive government initiatives, like India's USD 1 billion healthcare access program in 2024, enhance affordability in APAC.

Restraints

High costs of cardiac implant devices, coupled with implantation procedures, restrict access in emerging markets. Stringent regulatory approvals, such as FDA and EU MDR requirements tightened in 2024, increase development timelines. Limited reimbursement policies in developing regions hinder market penetration.

Segmentation Analysis

By Product Type: Coronary stents lead with a 30% share in 2024, driven by coronary heart disease prevalence. Implantable heart pumps grow rapidly due to rising heart failure cases.

By Application: Arrhythmia management dominates, followed by heart failure and coronary artery disease treatments.

By End-User: Hospitals hold the largest share, with outpatient clinics expanding for minimally invasive procedures.

Regional Analysis

North America commands a 40% market share in 2024, driven by high disposable incomes and advanced healthcare infrastructure in the U.S. Asia Pacific grows at a 9.2% CAGR, fueled by rising cardiovascular cases and healthcare investments in China and India. Europe sustains growth through robust healthcare systems and R&D investments.

This report equips industry experts with critical insights into market trends, regulatory landscapes, and competitive dynamics. It highlights opportunities in advanced device technologies and emerging markets while addressing cost and regulatory challenges. The rigorous methodology, blending primary and secondary data, ensures reliable projections, enabling stakeholders to navigate complexities and prioritize investments in this essential medical device sector.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2022 to 2024 & forecast data from 2025 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Segmentation

By Product Type

• Pacemakers
• Cardiac Resynchronization Therapy (CRT) devices
• Implantable Cardioverter Defibrillator (ICD)
• Transcatheter Heart Valves (TAVR/TAVI) & Surgical Prosthetic Valves
• Ventricular Assist Devices (VADs/LVADs)
• Cardiac Monitoring Implants
• Left Atrial Appendage (LAA) Closure Device
• Coronary Stents
• Prosthetic Heart Valves
• Insertable Cardiac Monitor (ICM)
• Implantable Heart Pump
• Leads, Generators, and Delivery Systems
• Others

By Distribution

• Tertiary Hospitals
• Community Hospitals
• Ambulatory Surgery Centers
• Cardiac Clinics

By Geography

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Italy
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• Japan
• India
• South Korea
• Taiwan
• Thailand
• Indonesia
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. CARDIAC IMPLANT DEVICES MARKET BY PRODUCT TYPE

• 5.1. Introduction
• 5.2. Pacemakers
• 5.3. Cardiac Resynchronization Therapy (CRT) devices
• 5.4. Implantable Cardioverter Defibrillator (ICD)
• 5.5. Transcatheter Heart Valves (TAVR/TAVI) & Surgical Prosthetic Valves
• 5.6. Ventricular Assist Devices (VADs/LVADs)
• 5.7. Cardiac Monitoring Implants
• 5.8. Left Atrial Appendage (LAA) Closure Device
• 5.9. Coronary Stents
• 5.10. Prosthetic Heart Valves
• 5.11. Insertable Cardiac Monitor (ICM)
• 5.12. Implantable Heart Pump
• 5.13. Leads, Generators, and Delivery Systems
• 5.14. Others

6. CARDIAC IMPLANT DEVICES MARKET BY DISTRIBUTION

• 6.1. Introduction
• 6.2. Tertiary Hospitals
• 6.3. Community Hospitals
• 6.4. Ambulatory Surgery Centers
• 6.5. Cardiac Clinics

7. CARDIAC IMPLANT DEVICES MARKET BY GEOGRAPHY

• 7.1. Introduction
• 7.2. North America
  • 7.2.1. USA
  • 7.2.2. Canada
  • 7.2.3. Mexico
• 7.3. South America
  • 7.3.1. Brazil
  • 7.3.2. Argentina
  • 7.3.3. Others
• 7.4. Europe
  • 7.4.1. United Kingdom
  • 7.4.2. Germany
  • 7.4.3. France
  • 7.4.4. Italy
  • 7.4.5. Spain
  • 7.4.6. Others
• 7.5. Middle East and Africa
  • 7.5.1. Saudi Arabia
  • 7.5.2. UAE
  • 7.5.3. Others
• 7.6. Asia Pacific
  • 7.6.1. China
  • 7.6.2. Japan
  • 7.6.3. India
  • 7.6.4. South Korea
  • 7.6.5. Taiwan
  • 7.6.6. Thailand
  • 7.6.7. Indosneisa
  • 7.6.8. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 8.1. Major Players and Strategy Analysis
• 8.2. Market Share Analysis
• 8.3. Mergers, Acquisitions, Agreements, and Collaborations
• 8.4. Competitive Dashboard

9. COMPANY PROFILES

• 9.1. Medtronic plc
• 9.2. Abbott Laboratories
• 9.3. Boston Scientific Corporation
• 9.4. Edwards Lifesciences Corporation
• 9.5. Biotronik SE & Co. KG
• 9.6. LivaNova PLC
• 9.7. Lepu Medical Technology Co., Ltd.
• 9.8. Asahi Kasei Corporation (Zoll Medical)
• 9.9. Abiomed, Inc.
• 9.10. SynCardia Systems, LLC
• 9.11. MicroPort Scientific Corporation:

10. RESEARCH METHODOLOGY